Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Workforce, Rules, Oversight and Government Reform, Armed Servi…
This bill establishes a federal "Medicare for All" national health insurance program providing comprehensive, no-cost-sharing coverage to all U.S. residents. It defines covered benefits (including long-term care, reproductive and gender-affirming care), provider participation rules, centralized budgeting and payment mechanisms (global budgets for institutions and a national fee schedule), annual drug price negotiation with backstop licensing authority, creation of a Universal Medicare Trust Fund to finance the program, and a two-year transition with an optional buy-in period.
Financing transparency and projected fiscal impacts versus program ambition.
Relative to its intended legislative type, this bill is a comprehensive substantive rewrite establishing a national health insurance program.
This bill establishes a federal "Medicare for All" national health insurance program providing comprehensive, no-cost-sharing coverage to all U.S. residents.
It defines covered benefits (including long-term care, reproductive and gender-affirming care), provider participation rules, centralized budgeting and payment mechanisms (global budgets for institutions and a national fee schedule), annual drug price negotiation with backstop licensing authority, creation of a Universal Medicare Trust Fund to finance the program, and a two-year transition with an optional buy-in period.
A comprehensive single‑payer overhaul with major fiscal, regulatory, and federalism shifts faces low enactment probability absent extraordinary political alignment or major compromise.
Relative to its intended legislative type, this bill is a comprehensive substantive rewrite establishing a national health insurance program. It couples detailed statutory mechanics (eligibility, benefits, provider rules, payment systems, trust fund, and many conforming amendments) with administrative implementation authority and oversight provisions.
Financing transparency and projected fiscal impacts versus program ambition.
These are examples from the analysis, not a ranked list of the most-affected groups.
Financing transparency and projected fiscal impacts versus program ambition.
Strongly favorable.
The bill creates universal, comprehensive coverage with no out-of-pocket costs, expands long-term care and reproductive and gender-affirming services, and enables drug price negotiation.
It aligns with priorities on equity, worker protections, and removing profit incentives from care.
Cautious/mixed.
Supports the goal of universal access and cost containment tools like drug negotiation, but concerned about fiscal details, execution risk, and potential disruption to existing employer-based coverage and provider capacity.
Would seek clearer finance and implementation safeguards.
Strongly opposed.
Views the bill as a large federal takeover of health care that ends most private coverage, expands bureaucracy, restricts provider compensation and incentives, and risks rationing and harms to innovation through drug licensing authority.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A comprehensive single‑payer overhaul with major fiscal, regulatory, and federalism shifts faces low enactment probability absent extraordinary political alignment or major compromise.
The bill has not accumulated any surfaced votes yet.
Financing transparency and projected fiscal impacts versus program ambition.
A comprehensive single‑payer overhaul with major fiscal, regulatory, and federalism shifts faces low enactment probability absent extraordi…
Relative to its intended legislative type, this bill is a comprehensive substantive rewrite establishing a national health insurance program. It couples detailed statutory mechanics (eligibility, benefits, provider rule…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.